Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News EuroPCR 2016

Embolic Protection in TAVR: If, When, What, and How Debated as Trials Wrap Up

Shelley Wood

May 20, 2016

Presentation EuroPCR 2016

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Presenter: Jens Erik Nielsen-Kudsk

May 20, 2016

News Conference News EuroPCR 2016

LAA Closure May Provide Solution for Stroke Prevention in Patients With Prior Intracerebral Hemorrhage

Yael L. Maxwell

May 18, 2016

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Conference News EuroPCR 2015

Sapien 3 Experience in Europe, Canada Shows Low Mortality, Paravalvular Leak at 30 Days

Yael L. Maxwell

May 21, 2015

News Conference News EuroPCR 2015

NOTION: 2-Year Data Show Positive Outlook for TAVR in Lower-Risk Patients

Yael L. Maxwell

May 19, 2015

News Conference News EuroPCR 2014

Benefit of LAA Closure Becomes Most Evident After 1 Year

Caitlin E. Cox

May 23, 2014

News Conference News EuroPCR 2014

UK Registry Finds Long-Term Survival After TAVR Depends on Patient Characteristics

Caitlin E. Cox

May 22, 2014

Presentation EuroPCR 2014

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Presenter: Jos? Ram?n L?pez-M?nguez

May 21, 2014

Advertisement

Embolic Protection in TAVR: If, When, What, and How Debated as Trials Wrap Up

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

LAA Closure May Provide Solution for Stroke Prevention in Patients With Prior Intracerebral Hemorrhage

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Sapien 3 Experience in Europe, Canada Shows Low Mortality, Paravalvular Leak at 30 Days

NOTION: 2-Year Data Show Positive Outlook for TAVR in Lower-Risk Patients

Benefit of LAA Closure Becomes Most Evident After 1 Year

UK Registry Finds Long-Term Survival After TAVR Depends on Patient Characteristics

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content